Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hemp-Derived CBG tested for anxiety relief in small study

NCT ID NCT05257044

Symptom relief Sponsor: Washington State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether cannabigerol (CBG), a compound from hemp, can improve mood, reduce anxiety, and ease stress. 38 adults who had used cannabis before took CBG or a placebo in a double-blind crossover design. Researchers also tracked side effects like sleepiness and dry mouth. The goal is to understand both the benefits and risks of CBG for mental well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cannabigerol (CBG)
What this could lead to
If it works, this could point toward a natural compound for easing anxiety and stress without serious side effects.
What could go wrong
This is a very early Phase 1 trial with only 38 people, so results may not apply widely. CBG could also cause sleepiness, dry mouth, or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

38 people

The number who actually took part.

Started

Mar 2022

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * 21+ years of age * reside in Washington state * own a smartphone * have access to a private environment where they can access a computer with a webcam connected to a high-quality and stable internet * speak fluent English * be literate * have experience using cannabis-based products without serious adverse reactions Exclusion Criteria * serious psychiatric disorders (e.g., psychotic disorder, bipolar disorder) * neurological and other serious medical conditions including head injury * pregnancy, or breastfeeding * use of illicit substances in past 2 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focus: to examine acute effects of CBG on anxiety, stress, and cognition are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focus: to examine acute effects of CBG on anxiety, stress, and cognition

Contacts and locations

Locations

  • Washington State University

    Pullman, Washington, 99164, United States